iBio Inc. closed 38.35% short of its 52-week high of $4.98, which the company achieved on March 28th.

The stock's fall snapped a two-day winning streak.

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.

In a regulatory filing, iBio (IBIO) disclosed that its director Antonio Parada bought 183.8K shares of common stock on January 10th in a total ...

iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...

An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling ...

iBio, Inc. has announced a collaboration with AstralBio Inc. to develop an innovative antibody targeting Activin E, a key factor in cardiometabolic disorders and obesity, using iBio's Machine ...

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...